FORUM MARKETS Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FORUM MARKETS Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.55M | Apr 1, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($450.52M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($14.18M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($19.94M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($38.73M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($20.32M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($10.88M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($25.39M) | Jul 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.04M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $123.8K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($3.1K) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($233.45M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($4.42M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($13.48M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.90M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($15.64M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.65M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($20.86M) | Jul 9, 2021 |
| FY2019 | Dec 31, 2018 | ($599.1K) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($343.9K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($3.1K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.40M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $2.30M | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $2.19M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $1.00M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.22M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.98M | Jul 9, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.05M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($1.17M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($10.92M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($12.13M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($19.37M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($3.87M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.32M) | Jul 9, 2021 |
| FY2019 | Dec 31, 2018 | ($789.2K) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($497.4K) | Apr 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $306.30M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $12.76M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $5.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $19.65M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $62.71M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $55.53M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $51.88M | Jul 9, 2021 |
| FY2019 | Dec 31, 2018 | $118.44M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $117.06M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $240.0K | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.88M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $3.51M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $5.39M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.31M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $23.39M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $25.25M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.31M | Jul 9, 2021 |
| FY2019 | Dec 31, 2018 | $4.57M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $4.23M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $218.1K | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $239.42M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $9.25M | Apr 1, 2026 |
| FY2025 | Dec 31, 2023 | ($127.0K) | Apr 1, 2026 |
| FY2024 | Dec 31, 2022 | $11.34M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $39.32M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $30.29M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $38.57M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($7.68M) | Jul 9, 2021 |
| FY2019 | Dec 31, 2017 | $5.00M | Apr 7, 2020 |
| FY2018 | Dec 31, 2016 | $21.9K | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 25, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $36.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $36.90M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $36.42M | Jul 9, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($592.04M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($141.52M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($127.34M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($107.41M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($68.68M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($48.36M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($37.47M) | Jul 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.16M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $120.7K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($3.1K) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.02M | Apr 1, 2026 |
| FY2020 | Dec 31, 2020 | $2.11M | Jul 9, 2021 |
| FY2020 | Dec 31, 2019 | $83.4K | Jul 9, 2021 |
| FY2020 | Dec 31, 2018 | $567.2K | Jul 9, 2021 |
| FY2019 | Dec 31, 2017 | $428.4K | Apr 7, 2020 |
| FY2018 | Dec 31, 2016 | $67.3K | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 20, 2020 | 50,000 | Mar 31, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (54) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | (28) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (52) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (387) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (12) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Apr 7, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (54) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | (28) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | (52) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (387) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (12) | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Apr 7, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.01M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 317,705 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 534,719 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 197,209 | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 1.70M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 26.17M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 13.85M | Jul 9, 2021 |
| FY2019 | Dec 31, 2018 | 4.10M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | 4.20M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 2.88M | Mar 29, 2018 |